20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T80055 | Beta-glucuronidase (bovine liver) | ||
Beta-glucuronidase, a critical lysosomal enzyme, is implicated in the breakdown of glucuronate-containing glycosaminoglycans [1]. | |||
T8254 | Chrysoobtusin | Others | |
Chrysoobtusin belongs to the class of organic compounds known as hydroxyanthraquinones. | |||
T81944 | LEAP-2 | Human liver expressed antimicrobial peptide-2 | |
LEAP-2 (Liver-expressed antimicrobial peptide 2) is a peptide of human origin with antimicrobial properties, initially identified in blood [1]. | |||
T16930 | SR9238 | Liver X Receptor | |
SR9238 is a synthetic agonist of liver X receptor inverse (IC50s: 214 nM and 43 nM for LXRα and LXRβ, respectively). | |||
T1801 | SR9243 | Liver X Receptor | |
SR9243, an LXR inverse agonist, can induce LXR-corepressor interaction; shows anticancer activity and selectively targets the lipogenesis and Warburg effect. | |||
T5178 | AZ876 | Liver X Receptor | |
AZ876 is a potent, highly selective LXR agonist with Ki/EC50 of 7/6 nM and 11/73 nM for hLXRα and hLXRβ respectively. | |||
T15427 | GSK2033 | Liver X Receptor | |
GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively). | |||
T6347 | Ki16198 | LPA Receptor , LPL Receptor | |
Ki16198 is the methyl ester of Ki16425, which is a LPA antagonist and inhibits LPA1- and LPA3-induced inositol phosphate production with Ki of 0.34 μM and 0.93 μM, respectively, shows weaker inhibition for LPA2, no activ... | |||
T11991 | Mefentrifluconazole | P450 , Antifungal | |
Mefentrifluconazole is a potent, selective and orally active fungal CYP51 (Kd= 0.5 nM) inhibitor, but shows less inhibitory activity on human aromatase (IC50=0.92 μM). Mefentrifluconazole is a novel azole derivative and ... | |||
T12580 | PTUPB | COX , Epoxide Hydrolase | |
PTUPB is a potent and dual inhibitor of sEH and COX-2 enzymes(IC50 of 0.9 nM and 1.26 μM, respectively). | |||
T7529 | Yamogenin | Others | |
Yamogenin is a diastereomer of diosgenin, which we have identified as the compound responsible for the anti-hyperlipidemic effect of fenugreek. | |||
T9215 | ELOVL6-IN-2 | Others | |
ELOVL6-IN-2 is a orally active and selective ELOVL6 inhibitor. | |||
T11428 | Glyco-Obeticholic acid | FXR | |
Glyco-Obeticholic acid is an active metabolite of Obeticholic acid. Obeticholic acid is an agonist of the farnesoid X receptor (FXR). | |||
T13092 | Tauro-Obeticholic acid | FXR | |
Tauro-Obeticholic acid is an active Obeticholic acid metabolite. Obeticholic acid is an orally bioavailable agonist of farnesoid-X receptor (FXR). | |||
T4S0878 | Prunetin | Prunusetin | ERK , Dehydrogenase , NF-κB |
1. Prunetin (Prunusetin) significantly reduces serum levels of inflammatory cytokines and mortality in mice challenged with lipopolysaccharide. 2. Prunetin mediates anti-obesity/adipogenesis effects by suppressing obesit... | |||
T2768 | Saikosaponin A | NF-κB , Antibacterial , Liver X Receptor | |
Saikosaponin A has a variety of pharmacological benefits, including antiepileptic, anti-osteoporosis, antioxidant, anti-in ammatory, immunomodulatory, and anti-bacterial activities. It can effectively attenuate neuropath... | |||
T2601 | Vidofludimus | SC12267,4sc-101 | Dehydrogenase , DNA/RNA Synthesis , Interleukin |
Vidofludimus (SC12267) (4SC-101, SC12267) is a novel small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). | |||
T3633 | Crenigacestat | LY3039478 | Gamma-secretase |
Crenigacestat (LY3039478) is an orally bioavailable Notch inhibitor with an IC50 of ~1 nM in most of the tumor cell lines tested. Crenigacestat effectively inhibits mutant Notch receptor activity. In a xenograft tumor mo... | |||
T10904 | CWP232228 | Wnt/beta-catenin | |
CWP232228, a potent and selective Wnt / β-catenin signaling inhibitor, antagonizes the binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 inhibits the formation and metastasis of tumors by inhibiting t... | |||
T15371 | Gardiquimod | TLR , HIV Protease | |
Gardiquimod is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7. Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells... |